Hospitalisation for heart failure and mortality associated with dipeptidyl peptidase 4 (DPP-4) inhibitor use in an unselected population of subjects with type 2 diabetes: A nested case-control study

BMJ Open

Volumn 5, Issue 6, 2015, Pages

  Giorda, Carlo B ^a   Picariello, Roberta ^b   Tartaglino, Barbara ^c   Marafetti, Lisa ^a   Di Noi, Fabiana ^a   Alessiato, Annalisa ^a   Costa, Giuseppe ^b,d   Gnavi, Roberto ^b  

^a ASL TO5   (Italy)

^b ASL TO3   (Italy)

^c Chai Medica Assoc   (Italy)

^d UNIVERSITY OF TURIN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLIBENCLAMIDE; GLIMEPIRIDE; INSULIN; PLACEBO; ANTIDIABETIC AGENT;

ADULT; ARTICLE; CONTROLLED STUDY; HEART FAILURE; HOSPITAL ADMISSION; HOSPITAL READMISSION; HOSPITALIZATION; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; RISK FACTOR; AGED; CASE CONTROL STUDY; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; FEMALE; MALE; STATISTICS AND NUMERICAL DATA; TREATMENT OUTCOME;

AGED; CASE-CONTROL STUDIES; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; FEMALE; HEART FAILURE; HOSPITALIZATION; HUMANS; HYPOGLYCEMIC AGENTS; MALE; RISK FACTORS; TREATMENT OUTCOME;

EID: 84930934027     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2015-007959     Document Type: Article

References (27)

1. Monami M, Dicembrini I, Nardini C, et al. Effects of glucagon-like peptide-1 receptor agonists on cardiovascular risk: a meta-analysis of randomized clinical trials. Diabetes Obes Metab 2014;16:38-47.
2. Scirica BM, Bhatt DL, Braunwald E, et al, AVOR-TIMI 53 Steering Committee and Investigators. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 2013;369:1317-26.
3. Scirica BM, Braunwald E, Raz I, et al, for the SAVOR-TIMI 53 Steering Committee and Investigators. Heart failure, saxagliptin and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial. Circulation 2014;130:1579-88.
4. Fonarow GC. Diabetes medications and heart failure: recognizing the risk. Circulation 2014;130:1565-7.
5. Scirica BM, Raz I, Cavender MA, et al, on behalf of the SAVOR-TIMI 53 Steering Committee and Investigators. Outcomes of patients with type 2 diabetes and known congestive heart failure treated with saxagliptin: analyses of the SAVOR-TIMI 53 Study. Poster number 5082 presented at American Heart Association 2013, Dallas, Texas, USA, 17 November 2013.
6. Monami M, Dicembrini I, Mannucci E. Dipeptidyl peptidase-4 inhibitors and heart failure: a meta-analysis of randomized clinical trials. Nutr Metab Cardiovasc Dis 2014;24:689-97.
7. Wang KL, Liu CJ, Huang CM, et al. Sitagliptin and the risk of hospitalization for heart failure: a population-based study. Int J Cardiol 2014;177:86-90.
8. Chen DY, Wang SH, Mao CT, et al. Sitagliptin and cardiovascular outcomes in diabetic patients with chronic kidney disease and acute myocardial infarction: A nationwide cohort study. Int J Cardiol 2015;181:200-6.
9. Weir DL, McAlister FA, Senthilselvan A, et al. Sitagliptin use in patients with diabetes and heart failure: a population-based retrospective cohort study. JACC Heart Fail 2014;2:573-82.
10. Kannel WB, Hjortland M, Castelli WP. Role of diabetes in congestive heart failure: the Framingham study. Am J Cardiol 1974;34:29-34.
11. Chae CU, Glynn TJ, Manson JE, et al. Diabetes predicts congestive heart failure risk in the elderly. Circulation 1998;98:721.
12. Bell DS. Heart failure: the frequent, forgotten, and often fatal complication of diabetes. Diabetes Care 2003;26:2433-41.
13. Eurich DT, McAlister FA, Blackburn DF, et al. Benefits and harms of antidiabetic agents in patients with diabetes and heart failure: systematic review. BMJ 2007;335:497.
14. Yu OH, Filion KB, Azoulay L, et al. Incretin-based drugs and the risk of congestive heart failure. Diabetes Care 2015;38:277-84.
15. Ussher JR, Drucker DJ. Cardiovascular actions of incretin-based therapies. Circ Res 2014;114:1788-803.
16. Khan MA, Deaton C, Rutter MK, et al. Incretins as a novel therapeutic strategy in patients with diabetes and heart failure. Heart Fail Rev 2013;18:141-8.
17. http://www.escardio.org/congresses/hf2013/congress-to-you/Pages/vildagliptin-shows-no-adverse-effect-ejection-fraction-diabeticpatients-with-heart-failure.aspx (accessed 18 Nov 2014).
18. Ayaori M, Iwakami N, Uto-Kondo H, et al. Dipeptidyl vasodilatation in type 2 diabetic patients. J Am Heart Assoc 2013;2:e003277.
19. Mogensen UM, Andersson C, Fosbol EL, et al. Cardiovascular safety of combination therapies with incretin-based drugs and metformin compared with a a combination of metformin and sulphonylurea in type 2 diabetes mellitus-a retrospective nationwide study. Diabetes Obes Metab 2014;16:1001-8.
20. Giorda C, Picariello R, Elisa Nada E, et al. The impact of adherence to screening guidelines and of diabetes clinics referral on morbidity and mortality in diabetes. PLoS ONE 2012;7:e33839.
21. Giorda CB. Could clinical inertia in part explain the unexpected association of insulin therapy with poorer cardiovascular outcomes in observational studies on diabetes? Diabetes Res Clin Pract 2011;92:e47-8.
22. Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359:1577-89.
23. Gerstein HC, Bosch J, Dagenais GR, et al, The ORIGIN Trial Investigators. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med 2012;367:319-28.
24. Giorda CB, Avogaro A, Maggini M, et al, for the Diabetes and Informatics Study Group. Incidence and risk factors for stroke in type 2 diabetic patients: the DAI study. Stroke 2007;38:1154-60.
25. Nichols GA, Hillier TA, Erbey JR, et al. Congestive heart failure in type 2 diabetes: prevalence, incidence, and risk factors. Diabetes Care 2001;24:1614-19.
26. Green JB, Bethel MA, Paul SK, et al. Rationale, design, and organization of a randomized, controlled Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) in patients with type 2 diabetes and established cardiovascular disease. Am Heart J 2013;166:983-9.
27. Margulies KB, Anstrom KJ, Hernandez AF, et al, Heart Failure Clinical Research Network. GLP-1 agonist therapy for advanced heart failure with reduced ejection fraction: design and rationale for the functional impact of GLP-1 for heart failure treatment study. Circ Heart Fail 2014;7:673-9.